JP2019514993A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019514993A5 JP2019514993A5 JP2018558764A JP2018558764A JP2019514993A5 JP 2019514993 A5 JP2019514993 A5 JP 2019514993A5 JP 2018558764 A JP2018558764 A JP 2018558764A JP 2018558764 A JP2018558764 A JP 2018558764A JP 2019514993 A5 JP2019514993 A5 JP 2019514993A5
- Authority
- JP
- Japan
- Prior art keywords
- poly
- cellulose
- copolymer
- pharmaceutical composition
- polyethylene glycol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 poly(vinyl pyrrolidone) Polymers 0.000 claims description 172
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 74
- 239000008194 pharmaceutical composition Substances 0.000 claims description 72
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 60
- 229920001577 copolymer Polymers 0.000 claims description 56
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 53
- 229920001223 polyethylene glycol Polymers 0.000 claims description 48
- 238000000034 method Methods 0.000 claims description 42
- 239000002202 Polyethylene glycol Substances 0.000 claims description 38
- 239000003795 chemical substances by application Substances 0.000 claims description 27
- 239000004698 Polyethylene Substances 0.000 claims description 26
- 229920000573 polyethylene Polymers 0.000 claims description 26
- 239000000314 lubricant Substances 0.000 claims description 22
- 229920003168 pharmaceutical polymer Polymers 0.000 claims description 21
- 239000001856 Ethyl cellulose Substances 0.000 claims description 20
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 20
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 20
- 229920001249 ethyl cellulose Polymers 0.000 claims description 20
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 20
- 239000000194 fatty acid Substances 0.000 claims description 20
- 235000011187 glycerol Nutrition 0.000 claims description 20
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 15
- 229920002554 vinyl polymer Polymers 0.000 claims description 15
- 229920000578 graft copolymer Polymers 0.000 claims description 14
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 14
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 14
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 14
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 14
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 12
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 12
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 12
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 12
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 12
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 12
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 12
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 12
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 12
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 11
- 229920003067 (meth)acrylic acid ester copolymer Polymers 0.000 claims description 10
- AVPDLWTUGIZJLH-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C([O-])=O.C[NH+](C)CCOC(=O)C(C)=C AVPDLWTUGIZJLH-UHFFFAOYSA-N 0.000 claims description 10
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 10
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 10
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 claims description 10
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 claims description 10
- 229920002301 cellulose acetate Polymers 0.000 claims description 10
- 229920006217 cellulose acetate butyrate Polymers 0.000 claims description 10
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 claims description 10
- YHAIUSTWZPMYGG-UHFFFAOYSA-L disodium;2,2-dioctyl-3-sulfobutanedioate Chemical compound [Na+].[Na+].CCCCCCCCC(C([O-])=O)(C(C([O-])=O)S(O)(=O)=O)CCCCCCCC YHAIUSTWZPMYGG-UHFFFAOYSA-L 0.000 claims description 10
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 10
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims description 10
- 229920000151 polyglycol Polymers 0.000 claims description 10
- 239000010695 polyglycol Substances 0.000 claims description 10
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 10
- 239000011118 polyvinyl acetate Substances 0.000 claims description 10
- 229940083575 sodium dodecyl sulfate Drugs 0.000 claims description 10
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 10
- 229950006451 sorbitan laurate Drugs 0.000 claims description 10
- 235000011067 sorbitan monolaureate Nutrition 0.000 claims description 10
- 239000004094 surface-active agent Substances 0.000 claims description 10
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 9
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 9
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 9
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims description 9
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 9
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 8
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 8
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 8
- 229920002125 Sokalan® Polymers 0.000 claims description 8
- 239000012062 aqueous buffer Substances 0.000 claims description 8
- 229960001631 carbomer Drugs 0.000 claims description 8
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 8
- 229960000913 crospovidone Drugs 0.000 claims description 8
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 8
- 239000004014 plasticizer Substances 0.000 claims description 8
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 8
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 6
- MHQJUHSHQGQVTM-HNENSFHCSA-N Octadecyl fumarate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)\C=C/C(O)=O MHQJUHSHQGQVTM-HNENSFHCSA-N 0.000 claims description 6
- 235000021314 Palmitic acid Nutrition 0.000 claims description 6
- 235000021355 Stearic acid Nutrition 0.000 claims description 6
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 6
- 239000008116 calcium stearate Substances 0.000 claims description 6
- 235000013539 calcium stearate Nutrition 0.000 claims description 6
- 229940078456 calcium stearate Drugs 0.000 claims description 6
- 229940049654 glyceryl behenate Drugs 0.000 claims description 6
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 6
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 claims description 6
- 229940046813 glyceryl palmitostearate Drugs 0.000 claims description 6
- 235000019359 magnesium stearate Nutrition 0.000 claims description 6
- 229940057948 magnesium stearate Drugs 0.000 claims description 6
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 6
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 6
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 6
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 6
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 6
- 229920000053 polysorbate 80 Polymers 0.000 claims description 6
- 239000011734 sodium Substances 0.000 claims description 6
- 229910052708 sodium Inorganic materials 0.000 claims description 6
- 239000008117 stearic acid Substances 0.000 claims description 6
- 229940071138 stearyl fumarate Drugs 0.000 claims description 6
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 claims description 6
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical group CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims description 6
- 229960003862 vemurafenib Drugs 0.000 claims description 6
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 claims description 6
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 238000009474 hot melt extrusion Methods 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 239000006186 oral dosage form Substances 0.000 claims description 4
- 238000000935 solvent evaporation Methods 0.000 claims description 4
- 239000013543 active substance Substances 0.000 claims description 3
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 claims description 3
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 claims description 3
- 229920002845 Poly(methacrylic acid) Polymers 0.000 claims description 2
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 claims description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 239000006185 dispersion Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- IWVKTOUOPHGZRX-UHFFFAOYSA-N methyl 2-methylprop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.COC(=O)C(C)=C IWVKTOUOPHGZRX-UHFFFAOYSA-N 0.000 claims description 2
- 239000005426 pharmaceutical component Substances 0.000 claims description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 2
- 238000010348 incorporation Methods 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims 1
- 229930003427 Vitamin E Natural products 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000005498 phthalate group Chemical class 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 229920000193 polymethacrylate Polymers 0.000 claims 1
- 235000019165 vitamin E Nutrition 0.000 claims 1
- 229940046009 vitamin E Drugs 0.000 claims 1
- 239000011709 vitamin E Substances 0.000 claims 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022088284A JP7458440B2 (ja) | 2016-05-09 | 2022-05-31 | 改善された薬物製剤 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662333482P | 2016-05-09 | 2016-05-09 | |
| US62/333,482 | 2016-05-09 | ||
| US201662334576P | 2016-05-11 | 2016-05-11 | |
| US62/334,576 | 2016-05-11 | ||
| PCT/US2017/031521 WO2017196712A1 (en) | 2016-05-09 | 2017-05-08 | Improved drug formulations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022088284A Division JP7458440B2 (ja) | 2016-05-09 | 2022-05-31 | 改善された薬物製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019514993A JP2019514993A (ja) | 2019-06-06 |
| JP2019514993A5 true JP2019514993A5 (https=) | 2020-06-18 |
| JP7112333B2 JP7112333B2 (ja) | 2022-08-03 |
Family
ID=60267508
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018558764A Active JP7112333B2 (ja) | 2016-05-09 | 2017-05-08 | 改善された薬物製剤 |
| JP2022088284A Active JP7458440B2 (ja) | 2016-05-09 | 2022-05-31 | 改善された薬物製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022088284A Active JP7458440B2 (ja) | 2016-05-09 | 2022-05-31 | 改善された薬物製剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20200009060A1 (https=) |
| EP (2) | EP4552641A3 (https=) |
| JP (2) | JP7112333B2 (https=) |
| CN (1) | CN109069460A (https=) |
| AU (1) | AU2017262586B2 (https=) |
| CA (1) | CA3022878C (https=) |
| IL (1) | IL262745B (https=) |
| MA (1) | MA44987A (https=) |
| WO (1) | WO2017196712A1 (https=) |
| ZA (1) | ZA201807446B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111511365A (zh) * | 2017-11-10 | 2020-08-07 | 分散技术有限责任公司 | 改进的药物制剂 |
| US20210128536A1 (en) * | 2019-11-01 | 2021-05-06 | Dispersol Technologies, Llc | Weakly basic drug and ionic polymer pharmaceutical formulations and methods of formation and administration thereof |
| KR20220123689A (ko) * | 2020-03-11 | 2022-09-08 | 사와이세이야쿠 가부시키가이샤 | 과립 및 그것을 이용한 제제 |
| WO2022094817A1 (en) * | 2020-11-04 | 2022-05-12 | Janssen Pharmaceuticals, Inc. | Pharmaceutical formulation |
| NL2028762B1 (en) * | 2021-07-16 | 2023-01-23 | Seranovo Holding B V | Micelle-generating formulations for enhanced bioavailability |
| CN116173018A (zh) * | 2021-11-26 | 2023-05-30 | 上海宣泰医药科技股份有限公司 | 一种达罗他胺药物组合物及其制备方法和用途 |
| CN114190538B (zh) * | 2021-12-21 | 2023-11-24 | 郑州轻工业大学 | 一种促β′晶型形成的油脂促结晶剂及应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE255883T1 (de) * | 1996-05-20 | 2003-12-15 | Janssen Pharmaceutica Nv | Fungizide mittel mit verbesserter bioverfügbarkeit |
| US20070218138A1 (en) * | 2006-03-20 | 2007-09-20 | Bittorf Kevin J | Pharmaceutical Compositions |
| CA3076115C (en) * | 2007-08-21 | 2022-06-28 | Board Of Regents, The University Of Texas System | Thermo-kinetic mixing for pharmaceutical applications |
| WO2009108077A2 (en) * | 2008-02-28 | 2009-09-03 | Bial - Portela & Ca., S.A. | Pharmaceutical composition for poorly soluble drugs |
| AU2009240586A1 (en) * | 2008-04-24 | 2009-10-29 | Evestra, Inc. | Oral contraceptive dosage forms comprising a progestogen dispersed in an enteric polymer and further comprising an estrogen |
| US20110065800A1 (en) * | 2008-05-14 | 2011-03-17 | Haihong Fan | Formulations for cathepsin k inhibitors |
| EP2568964B1 (en) * | 2010-05-10 | 2018-08-01 | Evonik Röhm GmbH | Pharmaceutical dosage form comprising one or more antiretroviral active ingredients |
| US20140039031A1 (en) * | 2011-02-23 | 2014-02-06 | Dispersol Technologies. LLC | Pharmaceutical formulations of acetyl-11-keto-b-boswellic acid, diindolylmethane, and curcumin for pharmaceutical applications |
| EP2654726A1 (en) * | 2011-03-08 | 2013-10-30 | Zalicus Pharmaceuticals Ltd. | Solid dispersion formulations and methods of use thereof |
| WO2014170026A1 (en) * | 2013-04-18 | 2014-10-23 | Zentiva, K.S. | Stabilized amorphous ticagrelor |
| WO2015152433A1 (en) * | 2014-03-31 | 2015-10-08 | Hanmi Pharm. Co., Ltd. | Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same |
| DK3131667T3 (da) * | 2014-04-18 | 2021-10-25 | Dispersol Technologies Llc | Flerhastigheds fremgangsmåde og blander til konservering af varmefølsomme portioner af et termokinetisk smelte blandet parti |
| WO2015175505A1 (en) * | 2014-05-15 | 2015-11-19 | Lundbeck Llc | Tetrabenazine modified release formulation |
| WO2016073421A1 (en) * | 2014-11-03 | 2016-05-12 | Dispersol Technologies, Llc | Improved formulations of vemurafenib and methods of making the same |
| CN104434809B (zh) * | 2014-12-10 | 2018-10-16 | 北京科莱博医药开发有限责任公司 | 一种奥拉帕尼固体分散体制剂及其制备方法 |
| JOP20170127A1 (ar) * | 2016-06-02 | 2017-12-02 | Gilead Pharmasset Llc | صيغة مشتركة مكونة من ثلاث مركبات مضادة للفيروسات |
-
2017
- 2017-05-08 WO PCT/US2017/031521 patent/WO2017196712A1/en not_active Ceased
- 2017-05-08 EP EP25151222.4A patent/EP4552641A3/en active Pending
- 2017-05-08 JP JP2018558764A patent/JP7112333B2/ja active Active
- 2017-05-08 CN CN201780028973.8A patent/CN109069460A/zh active Pending
- 2017-05-08 CA CA3022878A patent/CA3022878C/en active Active
- 2017-05-08 IL IL262745A patent/IL262745B/en unknown
- 2017-05-08 US US16/098,145 patent/US20200009060A1/en active Pending
- 2017-05-08 AU AU2017262586A patent/AU2017262586B2/en active Active
- 2017-05-08 EP EP17796620.7A patent/EP3454847A4/en not_active Withdrawn
- 2017-05-08 MA MA044987A patent/MA44987A/fr unknown
-
2018
- 2018-11-06 ZA ZA2018/07446A patent/ZA201807446B/en unknown
-
2022
- 2022-05-31 JP JP2022088284A patent/JP7458440B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019514993A5 (https=) | ||
| JP2018517734A5 (https=) | ||
| US9238007B2 (en) | Method for the production of a medicament containing tadalafil | |
| JP2014221816A5 (https=) | ||
| US11590127B2 (en) | Gastro-resistant formulation containing posaconazole | |
| CZ365597A3 (cs) | Třífázová farmaceutická forma s konstantním a řízeným uvolňováním amorfní účinné složky na jednorázové denní podávání | |
| CN102458373A (zh) | 生物利用度提高的包含难溶性药物的微球及其制备方法 | |
| RU2013141534A (ru) | Составы l-ментола, состоящие из множества частиц, и связанные с ними способы | |
| EP3793530A1 (en) | Solid dispersion containing ritonavir | |
| WO2015145462A1 (en) | Pharmaceutical compositions of dabigatran | |
| WO2013089479A1 (ko) | 세레콕시브 함유 고체분산체 및 그 제조방법 | |
| JP2025004239A (ja) | 結晶形 | |
| KR101895962B1 (ko) | 알리사르탄 이소프록실 고체 분산체 및 이를 포함하는 약제학적 조성물 | |
| MX2024010009A (es) | Formas de dosificacion oral de agonista de tr\03b2 vk2809 para el tratamiento de trastornos hepaticos y metodos de preparacion de las mismas. | |
| US20110274754A1 (en) | Oral tablet compositions of dexlansoprazole | |
| WO2014203137A2 (en) | Pharmaceutical compositions of tamsulosin or salts thereof | |
| AU2016231883B2 (en) | Pharmaceutical compositions of dimethyl fumarate | |
| EP3210599B1 (en) | Gastro-resistant formulation containing posaconazole and a polymeric precipitation inhibitor | |
| EP2564832A1 (en) | Solid dosage form of HIV protease inhibitors | |
| WO2025011569A1 (en) | Solid dispersion, preparation method, and pharmaceutical composition thereof | |
| US20100247646A1 (en) | Extended release tablets of nisoldipine | |
| RU2021102950A (ru) | Твердые фармацевтические композиции для лечения вируса гепатита с | |
| US20190030006A1 (en) | Surfactant-free hiv protease inhibitor composition and method of manufacturing thereof | |
| RU2017121505A (ru) | Композиция цефподоксима проксетила с пролонгированным высвобождением | |
| AU2016280148A1 (en) | Extended release Capecitabine capsules |